personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Intravitreal anti-VEGF therapy for choroidal neovascularization secondary to pathologic myopia: four year outcome

Session Details

Session Title: Quick Fire Free Paper Session 04

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 11:20

Venue: Hall C (Level 1)

First Author: J.Montero SPAIN

Co Author(s):    L. Arias   A. Carneiro   R. Silva   J. Ruiz-Moreno     

Abstract Details

Purpose:

To report the visual outcome after 4-year follow-up in a series of highly myopic eyes with choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (VEGF) drugs.

Setting:

Retrospective, non-randomized, multicenter, consecutive, interventional case series study.

Methods:

108 highly myopic eyes with CNV were treated by intravitreal anti-VEGF. The initial protocol (1 vs. 3 injections) was dictated by surgeons’ preferences and followed by a pro-re-nata monthly regime. Best-corrected visual acuity (BCVA) was evaluated at baseline and then monthly. The primary aim was to analyze BCVA changes. The effect of age, spherical equivalent (SE) and treating drug were evaluated as secondary objectives.

Results:

The mean age of the patients was 55 years (standard deviation (SD) 14, range 30 to 93). The average number of letters read at baseline was 49.5 (SD 18.0; 5 to 85); 58.3 (SD 18.9, 10 to 85) at 12 months; 57.4 (SD 20.9, 5 to 90) at 24 months; 56.2 (SD 22.0, 2 to 90) at 36 months and 54.3 (SD 22.6, 1 to 90) at 48 months (p<0.000, between initial vs. 12, 24 and 36 months and p=0.008 between initial vs. 48 months; Student’s t test for paired data). The mean total number of IVI was 4.6 (SD 5.1; 1 to 29). Age, SE and treating drug had no influence on the final visual outcome and number of injections required.

Conclusions:

Intravitreal bevacizumab and ranibizumab are effective therapies and show similar clinical effects in highly myopic CNV. Visual acuity gain is maintained at 4-year follow-up.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy